sel. reversible cov. immunoproteosome inh.

oral efficacy (1 mpk) in xeno., Ph. I in MM

from SBDD

Mol. Cancer Ther., May 27, 2021

Merck KGaA, Darmstadt, DE


The Merck LMP7 inhibitor, M3258, is an orally available, selective, and reversible inhibitor of the immunoproteasome proteolytic subunit, LMP7. In contrast to the constitutive proteasome, the immunoproteasome is predominantly expressed…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: